Shanghai Tyk Medicines Co. Ltd. and Tyk Medicines Inc. have identified poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.

Haisco Pharmaceutical Group Co. Ltd. has disclosed compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes and obesity.

Researchers at Korea Research Institute of Chemical Technology and University of Ulsan have described UBA6-specific E2 conjugating enzyme 1 (USE1) inhibitors reported to be useful for the treatment of cancer.

Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.

Morphic Therapeutic Inc. has identified compounds acting as integrin αvβ1 antagonists reported to be useful for the treatment of cancer, chronic kidney disease, diabetic nephropathy, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, interstitial lung diseases, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) and primary biliary cholangitis.

Scientists at Helmholtz Zentrum für Infektionsforschung GmbH, Rijksuniversiteit Groningen and Université de Lausanne have synthesized energy-coupling factor (ECF) transporter (bacterial) inhibitors reported to be useful for the treatment of enterococcal and streptococcal infections.

Maplight Therapeutics Inc. has disclosed G protein-coupled receptor GPR52 modulators reported to be useful for the treatment of neurological and psychiatric disorders.

Protier Biotech Inc. has patented protein/nucleic acid degraders comprising cereblon (CRBN)-binding agents covalently bound to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety via linker.

Work at Sensorium Therapeutics Inc. has led to the identification of new serotonin transporter (SERT) inhibitors reported to be useful for the treatment of depression, anxiety and stress disorders.